Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city

被引:1
|
作者
Lv, Riying [1 ]
Lu, Yanmeng [1 ]
Xiang, Wenyao [1 ]
Meng, Menglan [1 ]
Li, Shixiong [1 ,2 ]
机构
[1] Guigang City Peoples Hosp, Dept Infect Dis, Guigang, Guangxi, Peoples R China
[2] Guigang City Peoples Hosp, Dept Infect Dis, Guigang 537100, Guangxi, Peoples R China
关键词
ageing; Guigang; HCV; microclearance; telemedicine; NATURAL-HISTORY; EPIDEMIOLOGY; INFECTION; OUTCOMES;
D O I
10.1111/jvh.13922
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) represents a formidable menace to human health, necessitating urgent attention. The objective of this study was to assess the efficacy and safety of HCV health management in the city of Guigang which consists of five districts, employing a comprehensive multi-modal approach. The study systematically carried out HCV screening in Guigang city which consists of five districts, such as Gangbei District, Gangnan District, Guiping District, Qintang District, and Pingnan District from 1 January 2016 to 30 December 2022. The target population consisted of individuals residing in these aforementioned districts, falling within the age range of 30-75 years. A multidisciplinary HCV management team was established to deliver anti-HCV screening, diagnosis, and direct-acting antiviral (DAA) therapy. The primary outcome of interest was the achievement of sustained virologic response (SVR). A total of 2489 individuals were included as the target population, with 1694 individuals residing in Gangbei District, 202 in Gangnan District, 111 in Qintang District, 167 in Pingnan District, and 315 in Guiping District. Out of these individuals, 2478 were subjected to anti-HCV screening. The screening rates varied across the districts, ranging from a peak of 99.55% in Guigang City to a nadir of 98.41% in Guiping District. Remarkably, within Guigang City, a noteworthy enhancement was observed in the HCV-RNA diagnosis rate from 23.4% prior to program implementation to a remarkable 100% following 7 years of intervention and management. Furthermore, the diagnosis and treatment coordination rate experienced a substantial improvement, rising from 26.8% before program inception to 80%. Importantly, a total of 1180 individuals affected by hepatitis C were successfully cured, equating to a 100% cure rate. Logistic regression analysis revealed a significant association between serological status and factors such as Aging, bilirubin, and glutamic oxalacetic transaminase. The findings from our investigation unveil a pioneering HCV management model, exemplified by the Guigang model, which has contributed crucially to HCV microclearance efforts and serves as an invaluable reference for future initiatives.
引用
收藏
页码:208 / 215
页数:8
相关论文
共 50 条
  • [31] Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago
    Tatara, Eric
    Gutfraind, Alexander
    Collier, Nicholson T.
    Echevarria, Desarae
    Cotler, Scott J.
    Major, Marian E.
    Ozik, Jonathan
    Dahari, Harel
    Boodram, Basmattee
    PLOS ONE, 2022, 17 (03):
  • [32] Telemedicine Chronic Viral Hepatitis C Treatment during the Lockdown Period in Romania: A Pilot Study
    Doica, Irina Paula
    Florescu, Dan Nicolae
    Oancea, Carmen Nicoleta
    Turcu-Stiolica, Adina
    Subtirelu, Mihaela-Simona
    Dumitra, Gindrovel
    Rogoveanu, Ion
    Gheonea, Dan Ionut
    Ungureanu, Bogdan Silviu
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (07)
  • [33] Chronic viral hepatitis: policy, regulation, and strategies for its control and elimination in Ethiopia
    Shiferaw, Fassil
    Letebo, Meketew
    Bane, Abate
    BMC PUBLIC HEALTH, 2016, 16 : 1 - 13
  • [34] Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children
    Pluta, Magdalena
    Pokorska-Spiewak, Maria
    Aniszewska, Malgorzata
    Kowalik-Mikolajewska, Barbara
    Marczynska, Magdalena
    KLINISCHE PADIATRIE, 2021, 233 (05): : 211 - 215
  • [35] Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia
    Averhoff, Francisco
    Shadaker, Shaun
    Gamkrelidze, Amiran
    Kuchuloria, Tatia
    Gvinjilia, Lia
    Getia, Vladimer
    Sergeenko, David
    Butsashvili, Maia
    Tsertsvadze, Tengiz
    Sharvadze, Lali
    Zarkua, Jaba
    Skaggs, Beth
    Nasrullah, Muazzam
    JOURNAL OF HEPATOLOGY, 2020, 72 (04) : 680 - 687
  • [36] Management issues in chronic viral hepatitis: Hepatitis C
    Sievert, W
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (04) : 415 - 422
  • [37] Economic Analysis of National Program for Hepatitis C Elimination, Israel, 2023
    Dadon, Yuval
    Mimouni, Francis B.
    Toren, Ariella
    Morgenstern, Tal
    Barak, Lior
    Mendlovic, Joseph
    EMERGING INFECTIOUS DISEASES, 2024, 30 (10) : 2070 - 2078
  • [38] Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia
    Tsertsvadze, Tengiz
    Gamkrelidze, Amiran
    Nasrullah, Muazzam
    Sharvadze, Lali
    Morgan, Juliette
    Shadaker, Shaun
    Gvinjilia, Lia
    Butsashvili, Maia
    Metreveli, David
    Kerashvili, Vakhtang
    Ezugbaia, Marina
    Chkhartishvili, Nikoloz
    Abutidze, Akaki
    Kvaratskhelia, Valeri
    Averhoff, Francisco
    BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [39] Low viraemia at enrollment in children with chronic hepatitis C favours spontaneous viral clearance
    Chen, S. -T.
    Ni, Y. -H.
    Chen, P. -J.
    Chen, H. -L.
    Jeng, Y. -M.
    Lu, M. -Y.
    Wu, J. -F.
    Hsu, H. -Y.
    Chang, M. -H.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (11) : 796 - 801
  • [40] Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study
    McLeod, A.
    Hutchinson, S. J.
    Smith, S.
    Leen, C.
    Clifford, S.
    McAuley, A.
    Wallace, L. A.
    Barclay, S. T.
    Bramley, P.
    Dillon, J. F.
    Fraser, A.
    Gunson, R. N.
    Hayes, P. C.
    Kennedy, N.
    Peters, E.
    Templeton, K.
    Goldberg, D. J.
    HIV MEDICINE, 2021, 22 (05) : 334 - 345